MA53487A - Composés pyrazolo[3,4-b]pyridine utilisés en tant qu'inhibiteurs de kinases tam et met - Google Patents

Composés pyrazolo[3,4-b]pyridine utilisés en tant qu'inhibiteurs de kinases tam et met

Info

Publication number
MA53487A
MA53487A MA053487A MA53487A MA53487A MA 53487 A MA53487 A MA 53487A MA 053487 A MA053487 A MA 053487A MA 53487 A MA53487 A MA 53487A MA 53487 A MA53487 A MA 53487A
Authority
MA
Morocco
Prior art keywords
tam
pyrazolo
kinase inhibitors
compounds used
pyridine compounds
Prior art date
Application number
MA053487A
Other languages
English (en)
Inventor
Shelley Allen
Patrick Barbour
Adam Cook
Joshua Dahlke
John Gaudino
Ronald Jay Hinklin
Ellen Laird
Oren T Mcnulty
Qian Zhao
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of MA53487A publication Critical patent/MA53487A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA053487A 2018-08-30 2019-08-29 Composés pyrazolo[3,4-b]pyridine utilisés en tant qu'inhibiteurs de kinases tam et met MA53487A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862724829P 2018-08-30 2018-08-30
US201962858686P 2019-06-07 2019-06-07

Publications (1)

Publication Number Publication Date
MA53487A true MA53487A (fr) 2021-12-08

Family

ID=67928919

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053487A MA53487A (fr) 2018-08-30 2019-08-29 Composés pyrazolo[3,4-b]pyridine utilisés en tant qu'inhibiteurs de kinases tam et met

Country Status (25)

Country Link
US (3) US11104676B2 (fr)
EP (1) EP3843850B1 (fr)
JP (2) JP6970859B2 (fr)
KR (1) KR20210049898A (fr)
CN (1) CN112930215A (fr)
AU (3) AU2019330017B2 (fr)
BR (1) BR112021002722A2 (fr)
CA (1) CA3110502C (fr)
CL (1) CL2021000467A1 (fr)
CO (1) CO2021002651A2 (fr)
CR (1) CR20210098A (fr)
CU (1) CU20210015A7 (fr)
DO (1) DOP2021000038A (fr)
EC (1) ECSP21012498A (fr)
IL (1) IL281127B2 (fr)
MA (1) MA53487A (fr)
MX (1) MX2021001952A (fr)
NI (1) NI202100007A (fr)
PE (1) PE20211779A1 (fr)
PH (1) PH12021500017A1 (fr)
PY (1) PY1972250A (fr)
SG (1) SG11202101148UA (fr)
TW (1) TW202024071A (fr)
UY (1) UY38349A (fr)
WO (1) WO2020047184A1 (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200039938A1 (en) 2017-03-30 2020-02-06 Albert-Ludwigs-University Freiburg Kdm4 inhibitors
ES2985569T3 (es) * 2018-08-24 2024-11-06 Transthera Sciences Nanjing Inc Nuevo inhibidor de derivado de quinolina
TWI817018B (zh) 2019-06-28 2023-10-01 美商艾瑞生藥股份有限公司 用於治療ｂｒａｆ相關的疾病和失調症之化合物
AU2020342108B2 (en) 2019-09-06 2024-03-07 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Compound having Axl and c-Met kinase inhibitory activity, preparation thereof and application thereof
US20220298146A1 (en) * 2019-09-24 2022-09-22 Transthera Sciences (Nanjing), Inc. Heterocyclic derivative and use thereof
AU2020351782A1 (en) 2019-09-26 2022-04-21 Exelixis, Inc. Pyridone compounds and methods of use in the modulation of a protein kinase
BR112022017267A2 (pt) 2020-03-03 2022-12-13 Array Biopharma Inc Métodos para tratar o câncer usando (r)-n-(3-fluoro-4-((3-((1-hidroxipropan-2-il) amino)-1h-pirazolo[3,4-b]piridin-4-il)óxi)fenil)-3-(4-fluorofenil)-1-isopropil-2,4-dioxo-1,2,3,4-tetra-hidropirimidina-5-carboxamida
US12534479B2 (en) 2020-07-10 2026-01-27 Findcure Biosciences (Zhongshan) Co., Ltd. Triazine compound and composition and use thereof
EP4319748A4 (fr) * 2021-04-09 2025-02-26 Tachyon Therapeutics, Inc. Traitement du cancer par des inhibiteurs de kdm4
CN117355533A (zh) * 2021-06-22 2024-01-05 株式会社Lg化学 作为蛋白激酶抑制剂的新型化合物
WO2023002360A1 (fr) 2021-07-22 2023-01-26 Pfizer Inc. Formes solides et formulations d'un inhibiteur de tam et de c-met kinases
IT202100022682A1 (it) * 2021-09-01 2023-03-01 Luigi Frati Derivati pirimidinici e loro uso nel trattamento di tumori
CN115850301B (zh) * 2021-09-24 2024-11-15 中山医诺维申新药研发有限公司 吡唑酮类化合物及其组合物和用途
WO2023078408A1 (fr) * 2021-11-05 2023-05-11 上海海和药物研究开发股份有限公司 Combinaison pharmaceutique contenant un inhibiteur de la tyrosine kinase du récepteur met et son utilisation
CN118139620A (zh) * 2021-11-05 2024-06-04 上海海和药物研究开发股份有限公司 一种固体分散体、其制备方法及包含其的固体制剂
MX2024007444A (es) 2021-12-16 2024-09-02 Kinnate Biopharma Inc Inhibidores de cinasa met.
CN116003406B (zh) * 2021-12-29 2024-01-23 北京鞍石生物科技有限责任公司 杂芳环氮氧化合物及其制备方法和应用
CA3242316A1 (fr) 2021-12-30 2023-07-06 Biomea Fusion, Inc. Composes pyrazines utilises comme inhibiteurs de flt3
AU2024241633A1 (en) 2023-03-30 2025-11-06 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
CN121712509A (zh) 2023-05-04 2026-03-20 锐新医药公司 用于ras相关疾病或病症的组合疗法
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
CN116768868B (zh) * 2023-08-15 2023-12-08 云南省药物研究所 一种哒嗪酮硫代衍生物及其制备方法和应用
IL327306A (en) 2023-10-12 2026-05-01 Revolution Medicines Inc Macrocyclic RAS inhibitors
WO2025171296A1 (fr) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Inhibiteurs de ras
WO2025240847A1 (fr) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Inhibiteurs de ras
WO2025255438A1 (fr) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Procédés de traitement d'une maladie ou d'un trouble lié à la protéine ras
CN118878515B (zh) * 2024-06-19 2025-10-28 河北科技大学 一种取代苯胺嘧啶类化合物及其制备方法和用途
WO2025265060A1 (fr) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Compositions thérapeutiques et procédés de gestion d'effets liés au traitement
WO2026006747A1 (fr) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Inhibiteurs de ras
WO2026015825A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Utilisation d'un inhibiteur de ras pour traiter le cancer du pancréas
WO2026015796A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble lié à ras
WO2026015790A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble lié à ras
WO2026015801A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble liés à ras
WO2026050446A1 (fr) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Inhibiteurs de ras
WO2026072904A2 (fr) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions et méthodes de traitement du cancer du poumon
WO2026090116A2 (fr) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Inhibiteurs de ras
WO2026090245A1 (fr) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Utilisation d'inhibiteurs ras pour traiter un cancer
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US20050288290A1 (en) 2004-06-28 2005-12-29 Borzilleri Robert M Fused heterocyclic kinase inhibitors
WO2006014325A2 (fr) 2004-07-02 2006-02-09 Exelixis, Inc. Modulateurs de c-met et leur methode d'utilisation
PE20061119A1 (es) 2005-01-19 2006-11-27 Aventis Pharma Sa PIRAZOLO PIRIDINAS SUSTITUIDAS COMO INHIBIDORES DE CINASAS FAK, KDR Y Tie
MX2008011220A (es) * 2006-03-07 2008-09-11 Array Biopharma Inc Compuestos de pirazol heterobiciclicos y metodos de uso.
CN102816175B (zh) 2011-06-09 2015-12-16 上海汇伦生命科技有限公司 一种杂环并吡啶酮类化合物,其中间体、制备方法和用途
WO2013032797A2 (fr) * 2011-08-26 2013-03-07 New Hope R & D Bioscience, Inc. Composés oxétane-3,3-dicarboxamides et leurs procédés de fabrication et d'utilisation
WO2013043715A1 (fr) * 2011-09-19 2013-03-28 Genentech, Inc. Polythérapies comportant des antagonistes de c-met et de b-raf
UY34451A (es) * 2011-11-14 2013-05-31 Cephalon Inc Derivados de uracilo como inhibidores de la quinasa axl y c-met
US10028956B2 (en) 2013-08-02 2018-07-24 Ignyta, Inc. Methods of treating various cancers using an AXL/cMET inhibitor in combination with other agents
CA2934667A1 (fr) * 2013-12-26 2015-07-02 Ignyta, Inc. Derives de pyrazolo[1,5-a]pyridine et leurs procedes d'utilisation
WO2016004305A2 (fr) 2014-07-02 2016-01-07 Pharmacyclics Llc Inhibiteurs de la tyrosine kinase de bruton
KR20170036037A (ko) 2014-07-31 2017-03-31 노파르티스 아게 조합 요법
GB201509338D0 (en) 2015-05-29 2015-07-15 Bergenbio As Combination therapy
KR101829998B1 (ko) 2015-11-04 2018-02-19 롬엔드하스전자재료코리아유한회사 착색 감광성 수지 조성물 및 이를 이용한 차광성 스페이서
CN114456176B (zh) * 2016-03-28 2024-08-30 因赛特公司 作为tam抑制剂的吡咯并三嗪化合物
JP2019525934A (ja) 2016-07-29 2019-09-12 イーライ リリー アンド カンパニー 癌の治療に使用するためのメレスチニブおよび抗ｐｄ−ｌ１または抗ｐｄ−１阻害剤を用いた組み合わせ治療
US20190185567A1 (en) 2016-08-01 2019-06-20 Ignyta, Inc. Combinations for the treatment of cancer
US20190224200A1 (en) 2016-08-24 2019-07-25 Ignyta, Inc. Combinations for the treatment of cancer
EP3541384A1 (fr) 2016-11-16 2019-09-25 Eli Lilly and Company Traitement du cancer à l'aide d'une ou de plusieurs mutations de saut d'exon 14 ou d'un phénotype de saut d'exon 14
CN108250200A (zh) 2016-12-28 2018-07-06 中国科学院上海药物研究所 一种具有Axl抑制活性的化合物及其制备和应用
BR102018007822A2 (pt) 2017-04-20 2018-11-06 Gilead Sciences, Inc. composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
JP7377798B2 (ja) 2017-11-24 2023-11-10 南京明徳新薬研発有限公司 ｃ－ＭＥＴ／ＡＸＬ阻害剤としてのウラシル系化合物
WO2019113190A1 (fr) 2017-12-07 2019-06-13 Array Biopharma Inc. Composés de pyridine bicycliques fusionnés utilisés en tant qu'inhibiteurs de kinases tam

Also Published As

Publication number Publication date
CA3110502C (fr) 2023-10-03
EP3843850B1 (fr) 2023-11-15
MX2021001952A (es) 2021-04-19
UY38349A (es) 2020-03-31
KR20210049898A (ko) 2021-05-06
DOP2021000038A (es) 2021-04-15
AU2022202946B2 (en) 2023-08-03
CN112930215A (zh) 2021-06-08
AU2022221514A1 (en) 2022-09-22
AU2022202946A1 (en) 2022-05-26
AU2019330017B2 (en) 2022-05-26
IL281127A (en) 2021-04-29
PH12021500017A1 (en) 2021-09-13
AU2019330017A1 (en) 2021-03-04
TW202024071A (zh) 2020-07-01
JP7337133B2 (ja) 2023-09-01
EP3843850A1 (fr) 2021-07-07
PY1972250A (es) 2022-04-12
CA3110502A1 (fr) 2020-03-05
BR112021002722A2 (pt) 2021-08-10
JP2022009720A (ja) 2022-01-14
CU20210015A7 (es) 2021-10-12
JP2021527114A (ja) 2021-10-11
CO2021002651A2 (es) 2021-03-08
US11780835B2 (en) 2023-10-10
CR20210098A (es) 2021-07-01
US11104676B2 (en) 2021-08-31
PE20211779A1 (es) 2021-09-08
SG11202101148UA (en) 2021-04-29
ECSP21012498A (es) 2021-03-31
JP6970859B2 (ja) 2021-11-24
AU2022221514B2 (en) 2023-11-02
IL281127B1 (en) 2023-12-01
US20240174666A1 (en) 2024-05-30
CL2021000467A1 (es) 2021-10-22
US20200079770A1 (en) 2020-03-12
US20230011441A1 (en) 2023-01-12
IL281127B2 (en) 2024-04-01
WO2020047184A1 (fr) 2020-03-05
NI202100007A (es) 2021-06-22

Similar Documents

Publication Publication Date Title
IL281127A (en) Pyrazolo[3,4-b]pyridine compounds as inhibitors of tam and met kinases
MA53675A (fr) Composés substitués de pyrazolo[1,5-a]pyridine en tant qu'inhibiteurs de la kinase ret
MA51846A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de kinases
MA49570A (fr) Composés bicycliques pyrazolo et triazolo utilisés en tant qu'inhibiteurs de kinase jak
MA49888A (fr) Composés macrocycliques utilisés en tant qu'inhibiteurs de kinase ros1
MA52360A (fr) Dérivés de 2-amino-pyridine ou de 2-amino-pyrimidine utilisés en tant qu'inhibiteurs de kinases dépendantes des cyclines
CY1125460T1 (el) Ενωσεις ιμιδαζο [4,5-d]πυρρολο [2,3-β]πυριδινης ως αναστολεις κινασων janus
MA53377A (fr) Composés de pyridin-2-one utiles en tant qu'antagonistes de smarca2
EP3997087A4 (fr) Composés bicycliques hétéroaromatiques fusionnés substitués utilisés en tant qu'inhibiteurs de kinase et leur utilisation
CL2019000942A1 (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret.
MA53726A (fr) Composés pyrazolo[4,3-d]pyrimidine en tant que modulateurs des alk2 et/ou fgfr
MA52593A (fr) 1h-pyrazolo[4,3-b]pyridines en tant qu'inhibiteurs pde1
MA47013A (fr) Composés benzolactames utilisés en tant qu'inhibiteurs de protéine kinase
MX386481B (es) Imidazopirrolopiridina como inhibidores de la familia de quinasas jak
MA43169A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma
MA46264A (fr) Dérivés pyrazolo[1,5-a]pyridine et leur utilisation en tant qu'agents de lutte antiparasitaire
MA49956A (fr) Composés de pyrimidine utilisés en tant qu'inhibiteurs de kinase jak
FR25C1047I1 (fr) Aminopyrazoles en tant qu'inhibiteurs sélectifs de janus kinase
MA52987A (fr) Dérivés de pyrazolo[1,5-a]pyrazin-4-yl en tant qu'inhibiteurs de jak
MA54551A (fr) Composés d'imidazopyridazine et d'imidazopyridine utilisés en tant qu'inhibiteurs de la kinase 2 de type récepteur de l'activine
MA51438A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de lsd1
MA41551A (fr) Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
EP3706749A4 (fr) Composés macrocycliques en tant qu'inhibiteurs de kinase trk et leurs utilisations
SG11201907095UA (en) DERIVATIVES OF N-CYCLOALKYL/HETEROCYCLOALKYL-4-(IMIDAZO [1,2-a]PYRIDINE)PYRIMIDIN-2-AMINE AS THERAPEUTIC AGENTS
MA49374A (fr) Composés hétéroaromatiques utilisés en tant qu'inhibiteurs de vanine